New Drug Modalities – Asrar Qureshi’s Blog Post 1047

Asrar Qureshi’s blog discusses the Boston Consulting Group’s second annual report on the growth of new drug modalities. It highlights advancements in antibodies, recombinant products, cell therapies, gene therapies, and mRNA applications, emphasizing their implications for biopharma companies and patient care. The future of these modalities depends on their unique benefits and market speed.
Share
View Post

Expected Changes for Contract Research Organizations – Asrar Qureshi’s Blog Post #1040

This blog post by Asrar Qureshi discusses the role of Contract Research Organizations (CROs) in pharmaceutical development, including their services like clinical trial management and regulatory support. It highlights challenges and evolving trends in the industry, such as technology integration and changing sponsor needs, emphasizing the importance of adaptation for CROs’ future success.
Share
View Post

Pharma & the Future: Powered by Partnership & Patient Experience – Asrar Qureshi’s Blog Post 993

This blogpost provides a summary of a new Whitepaper on patient engagement within the pharmaceutical industry. It discusses the shift towards prioritizing patients, driven by global and local initiatives, and the challenges and opportunities in measuring the impact of patient engagement. It also highlights the importance of strategic partnerships and technology in driving the industry’s future success.
Share